Efficacy of Biologics in Patients with Allergic Bronchopulmonary Aspergillosis: A Systematic Review and Meta-Analysis
Lung · 2024-08 · 202 (4) · 367-383
DOI: 10.1007/s00408-024-00717-y ↗Kurz gefasst
Metaanalyse in der Zeitschrift Lung, online erschienen am 19.06.2024. Verfasst von Xiaoying Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Dep…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Aspergillosis, Allergic Bronchopulmonary, Biological Products, Immunoglobulin E. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 152 Literaturangaben. Gefördert von: Department of Science and Technology of Guangdong Province, Guangzhou Laboratory, Zhong Nanshan Medical Foundation of Guangdong Province.
Abstract (Originalsprache)
BACKGROUND: Treatment of allergic bronchopulmonary aspergillosis (ABPA) is challenging. Biological therapies have been reported as adjunctive treatments for ABPA, primarily in case series or case reports. This study aimed to analyze the efficacy of biologics for managing ABPA both qualitatively and quantitatively. METHODS: All articles on APBA published in October 2023 were searched in PubMed, Web of Science, ClinicalTrials.gov, and Embase databases. The effects of interest were the mean changes from baseline for outcomes, including exacerbation rates, oral corticosteroids usage (OCS), and total immunoglobulin E (IgE) levels. Reported outcomes were quantitatively synthesized by usual or individual patient data (IPD) meta-analyses. PROSPERO registration number: CRD42022373396. RESULTS: A total of 86 studies were included in the systematic review including 346 patients. Sixteen studies on omalizumab were pooled for the usual meta-analysis. Omalizumab therapy significantly reduced exacerbation rates (- 2.29 [95%CI - 3.32, - 1.26]), OCS dosage (- 10.91 mg [95%CI - 18.98, - 2.85]), and total IgE levels (- 273.07 IU/mL [95%CI - 379.30, - 166.84]), meanwhile improving FEV1% predicted (10.09% [95%CI 6.62, 13.55]). Thirty-one studies on dupilumab, mepolizumab, or benralizumab were pooled to perform an IPD meta-analysis, retrospectively. Both dupilumab and mepolizumab significantly reduced exacerbation rates, OCS, and total IgE levels. Benralizumab showed a similar trend, but it was not statistically significant. Tezepelumab showed weak evidence of its effects on ABPA. All five biologics led to milder clinical symptoms (e.g., cough, wheezing) with serious adverse effects that happened once in omalizumab treatment. CONCLUSION: These results indicate the clinical benefit of omalizumab, dupilumab, and mepolizumab in patients with ABPA. Further randomized, controlled studies with a larger sample size and longer follow-up are needed to confirm these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Department of Allergy and Clinical Immunology, Joint International Resear…
- Department of Respiratory and Critical Care Medicine, People's Hospital of Yangjiang, Yangjiang, Guangdong, China.
- Department of Medicine, Firestone Institute for Respiratory Health, St. Joseph's Healthcare and McMaster University, Hamilton, ON, Canada.
- Guangzhou National Lab, Guangzhou, People's Republic of China. chen_rch@163.com.
Förderung
- Department of Science and Technology of Guangdong Province
- Guangzhou Laboratory
- Zhong Nanshan Medical Foundation of Guangdong Province
Zitieren
APA
Chen, X., Zhi, H., Wang, X., Zhou, Z., Luo, H., Li, J., Sehmi, R., O'Byrne, P. M., & Chen, R. (2024). Efficacy of Biologics in Patients with Allergic Bronchopulmonary Aspergillosis: A Systematic Review and Meta-Analysis. Lung, 202(4), 367-383. https://doi.org/10.1007/s00408-024-00717-y
Vancouver
Chen X, Zhi H, Wang X, Zhou Z, Luo H, Li J, et al. Efficacy of Biologics in Patients with Allergic Bronchopulmonary Aspergillosis: A Systematic Review and Meta-Analysis. Lung. 2024;202(4):367-383. doi:10.1007/s00408-024-00717-y
BibTeX
@article{Chen2024,
author = {Chen, Xiaoying and Zhi, Haopeng and Wang, Xiaohu and Zhou, Zicong and Luo, Huiting and Li, Jing and Sehmi, Roma and O'Byrne, Paul M and Chen, Ruchong},
title = {Efficacy of Biologics in Patients with Allergic Bronchopulmonary Aspergillosis: A Systematic Review and Meta-Analysis},
journal = {Lung},
year = {2024},
volume = {202},
number = {4},
pages = {367--383},
doi = {10.1007/s00408-024-00717-y}
}
EUVIMED